Literature DB >> 8754775

Octapeptide somatostatin analog SMS 201-995 induces translocation of intracellular PTP1C to membranes in MCF-7 human breast adenocarcinoma cells.

C B Srikant1, S H Shen.   

Abstract

Somatostatin (SST) analogs exert direct antiproliferative actions in pancreatic, pituitary, and mammary tumor cells in vitro. SST receptor (SSTR)-mediated induction of membrane-associated protein tyrosine phosphatase (PTP) activity has been implicated in its anti-proliferative signaling by virtue of its ability to dephosphorylate and inactivate growth factor receptor kinases. Recently, a PTP-containing Src homology 2 domain, identified as PTP1C/SHPTP1/SHP/HCP, was found to be associated with SSTR in rat pancreatic acinar cell membranes. In the present study we investigated the antiproliferative action of the octapeptide SST analog SMS 201-995 (OCT) and its effect on PTP activity in MCF-7 human breast adenocarcinoma cells. We report here that OCT does not directly stimulate membrane-associated PTP activity, but induces translocation of intracellular PTP to the membrane in MCF-7 cells preincubated with the peptide in a time- and concentration-dependent manner. We demonstrate that this is due at least in part to OCT-induced recruitment of cytosolic PTP1C. OCT-induced recruitment of PTP1C to the cell surface as well as its ability to inhibit the growth of MCF-7 cells was G protein dependent and inhibited by orthovanadate. These findings suggest that translocation of cytosolic PTP1C by SST analogs to the cell surface is an early event in its antiproliferative signaling in tumor cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8754775     DOI: 10.1210/endo.137.8.8754775

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  8 in total

1.  Gbeta gamma -independent constitutive association of Galpha s with SHP-1 and angiotensin II receptor AT2 is essential in AT2-mediated ITIM-independent activation of SHP-1.

Authors:  Ying-Hong Feng; Yan Sun; Janice G Douglas
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-09       Impact factor: 11.205

Review 2.  Molecular pharmacology of somatostatin receptor subtypes.

Authors:  Y C Patel
Journal:  J Endocrinol Invest       Date:  1997-06       Impact factor: 4.256

Review 3.  International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature.

Authors:  Thomas Günther; Giovanni Tulipano; Pascal Dournaud; Corinne Bousquet; Zsolt Csaba; Hans-Jürgen Kreienkamp; Amelie Lupp; Márta Korbonits; Justo P Castaño; Hans-Jürgen Wester; Michael Culler; Shlomo Melmed; Stefan Schulz
Journal:  Pharmacol Rev       Date:  2018-10       Impact factor: 25.468

4.  Angiotensin II type 2 receptors mediate inhibition of mitogen-activated protein kinase cascade and functional activation of SHP-1 tyrosine phosphatase.

Authors:  K Bedecs; N Elbaz; M Sutren; M Masson; C Susini; A D Strosberg; C Nahmias
Journal:  Biochem J       Date:  1997-07-15       Impact factor: 3.857

Review 5.  Cross-talk and modulation of signaling between somatostatin and growth factor receptors.

Authors:  Ujendra Kumar
Journal:  Endocrine       Date:  2011-08-26       Impact factor: 3.633

6.  Human somatostatin receptor mediated antiproliferative action evokes subtype selective cytotoxic and cytostatic signaling.

Authors:  C B Srikant
Journal:  Yale J Biol Med       Date:  1997 Sep-Dec

7.  Peptide receptor targeting in cancer: the somatostatin paradigm.

Authors:  Federica Barbieri; Adriana Bajetto; Alessandra Pattarozzi; Monica Gatti; Roberto Würth; Stefano Thellung; Alessandro Corsaro; Valentina Villa; Mario Nizzari; Tullio Florio
Journal:  Int J Pept       Date:  2013-02-07

8.  Indirect antiproliferative effect of the somatostatin analog octreotide on MIA PaCa-2 human pancreatic carcinoma in nude mice.

Authors:  G Weckbecker; F Raulf; D Bodmer; C Bruns
Journal:  Yale J Biol Med       Date:  1997 Sep-Dec
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.